조직 및 계약 가격을 보려면 로그인를 클릭합니다.
크기 선택
보기 변경
제품정보 (DICE 배송 시 비용 별도)
실험식(Hill 표기법):
C39H76O8PNa
CAS 번호:
Molecular Weight:
726.98
MDL number:
UNSPSC Code:
51191904
NACRES:
NA.25
description
1,2-distearoyl-sn-glycero-3-phosphate (sodium salt)
assay
>99% (TLC)
form
powder
packaging
pkg of 1 × 25 mg (830865P-25mg), pkg of 1 × 500 mg (830865P-500mg)
manufacturer/tradename
Avanti Research™ - A Croda Brand
lipid type
cardiolipins
phospholipids
shipped in
dry ice
storage temp.
−20°C
SMILES string
[Na+].[P](=O)([O-])(OC[C@H](OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC)O
InChI
1S/C39H77O8P.Na/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-38(40)45-35-37(36-46-48(42,43)44)47-39(41)34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2;/h37H,3-36H2,1-2H3,(H2,42,43,44);/q;+1/p-1/t37-;/m1./s1
InChI key
ALPWRKFXEOAUDR-GKEJWYBXSA-M
General description
Phosphatidic acid (PA) has two fatty acids and one phosphate group attached to a glycerol backbone. The two fatty acids are present at position sn-1 and sn-2 of the C-atoms and the phosphate group is present in the sn-3 position of the C-atom.
Application
18:0 PA may be used:
- as a component in the bilayer to study its vesiculation ability on different coat protein I (COPI) fission factor
- to study its effects on intracellular Ca2+ concentration ([Ca2+]i) in C6 rat glioma and L2071 mouse fibroblast cells
- to study its effects on phosphorylation of cytochrome b(558) alpha chain (p22phox)
Biochem/physiol Actions
Phosphatidic acid (PA) acts as a biosynthetic precursor for the production of membrane glycerophospholipid and triacylglycerol. It participates in the modulation of mammalian target of rapamycin (mTOR) pathway. It may also participate in membrane trafficking, specifically in membrane fusion and fission.
Packaging
20 mL Clear Glass Screw Cap Vial (830865P-500mg)
5 mL Amber Glass Screw Cap Vial (830865P-25mg)
Legal Information
Avanti Research is a trademark of Avanti Polar Lipids, LLC
저장 등급
13 - Non Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Yang Liu et al.
Nature communications, 10(1), 5108-5108 (2019-11-11)
Mounting evidence suggests that the tumor microenvironment is profoundly immunosuppressive. Thus, mitigating tumor immunosuppression is crucial for inducing sustained antitumor immunity. Whereas previous studies involved intratumoral injection, we report here an inhalable nanoparticle-immunotherapy system targeting pulmonary antigen presenting cells (APCs)
Seung-Yeol Park et al.
Nature communications, 10(1), 3409-3409 (2019-08-01)
Studies on vesicle formation by the Coat Protein I (COPI) complex have contributed to a basic understanding of how vesicular transport is initiated. Phosphatidic acid (PA) and diacylglycerol (DAG) have been found previously to be required for the fission stage
Qiang Cheng et al.
Nature nanotechnology, 15(4), 313-320 (2020-04-07)
CRISPR-Cas gene editing and messenger RNA-based protein replacement therapy hold tremendous potential to effectively treat disease-causing mutations with diverse cellular origin. However, it is currently impossible to rationally design nanoparticles that selectively target specific tissues. Here, we report a strategy
국제 무역 품목 번호
| SKU | GTIN |
|---|---|
| 830865P-500MG | 04061835228478 |
| 830865P-25MG | 04061835228461 |